Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1981 2
1984 2
1988 3
1989 2
1990 2
1999 2
2002 1
2003 1
2006 1
2007 3
2008 3
2009 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
The discovery of GSK221149A: a potent and selective oxytocin antagonist.
Liddle J, Allen MJ, Borthwick AD, Brooks DP, Davies DE, Edwards RM, Exall AM, Hamlett C, Irving WR, Mason AM, McCafferty GP, Nerozzi F, Peace S, Philp J, Pollard D, Pullen MA, Shabbir SS, Sollis SL, Westfall TD, Woollard PM, Wu C, Hickey DM. Liddle J, et al. Among authors: mccafferty gp. Bioorg Med Chem Lett. 2008 Jan 1;18(1):90-4. doi: 10.1016/j.bmcl.2007.11.008. Epub 2007 Nov 6. Bioorg Med Chem Lett. 2008. PMID: 18032036
Characterization of neuromedin U effects in canine smooth muscle.
Westfall TD, McCafferty GP, Pullen M, Gruver S, Sulpizio AC, Aiyar VN, Disa J, Contino LC, Mannan IJ, Hieble JP. Westfall TD, et al. Among authors: mccafferty gp. J Pharmacol Exp Ther. 2002 Jun;301(3):987-92. doi: 10.1124/jpet.301.3.987. J Pharmacol Exp Ther. 2002. PMID: 12023529
N-((1S)-1-{[4-((2S)-2-{[(2,4-dichlorophenyl)sulfonyl]amino}-3-hydroxypropanoyl)-1-piperazinyl]carbonyl}-3-methylbutyl)-1-benzothiophene-2-carboxamide (GSK1016790A), a novel and potent transient receptor potential vanilloid 4 channel agonist induces urinary bladder contraction and hyperactivity: Part I.
Thorneloe KS, Sulpizio AC, Lin Z, Figueroa DJ, Clouse AK, McCafferty GP, Chendrimada TP, Lashinger ES, Gordon E, Evans L, Misajet BA, Demarini DJ, Nation JH, Casillas LN, Marquis RW, Votta BJ, Sheardown SA, Xu X, Brooks DP, Laping NJ, Westfall TD. Thorneloe KS, et al. Among authors: mccafferty gp. J Pharmacol Exp Ther. 2008 Aug;326(2):432-42. doi: 10.1124/jpet.108.139295. Epub 2008 May 22. J Pharmacol Exp Ther. 2008. PMID: 18499743
23 results